Nav: Home

UAEU licenses BioLegend (USA) to use 4 of its patents in order to diagnose Parkinson's disease

May 31, 2016

The United Arab Emirates University (UAEU) has signed a licensing agreement with USA-based global pharmaceutical company BioLegend, Inc. to use four different UAEU patents in biotechnology. The license was granted in order to develop diagnostic tools for the early detection of Parkinson's Disease and possibly other neurological diseases.

The technology was developed at UAEU and is patent protected in the USA, the European Union and other countries and regions worldwide. Dr. Ali Rashid Al Noaimi, Vice Chancellor of UAEU, signed the agreement on behalf of the university, while Dr. Gene Lay, the CEO and founder of BioLegend signed on behalf of the US company.

His Excellency Dr. Ali Rashid Al Nuaimi, Vice Chancellor of UAEU, stressed that this patent agreement was the second of its kind at UAEU. This is yet more evidence of the university's pursuit of excellence in order to follow the directives of the national leadership headed by His Highness Sheikh Khalifa Bin Zayed Al Nahyan, the President of UAE; and in accordance with the vision of His Highness Sheikh Mohammed Bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai. Such directives are further supported by His Highness General Sheikh Mohammed Bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the Armed Forces. This is also in tune with UAE Vision 2021. The Vice Chancellor added that UAEU reflects the leadership's focus on healthcare. Finally, he also added that, "the knowledge-based economy is part of the global economy and our national university should protect and market its technological discoveries and collaborate with industrial leaders globally and within the country."

Dr. Al Nuaimi also welcomed the announcement by saying that UAEU was honoured to cooperate with a global pharmaceutical company that specialized in brain diseases and neurological research as just such research is being carried out at the university. He also highlighted the importance of protecting research results by filing patent applications to protect the new discoveries: "UAEU has more than 80 different new inventions and around 190 patent applications in its portfolio, of which 36 have already been granted."

Dr. Gene Lay added that BioLegend were, "happy to have a partnership with United Arab Emirates University and is committed to the commercial development and exploitation of these patents." He further added that BioLegend was striving to provide quality research reagents and expert technical support to the worldwide scientific. Their mission is to accelerate research and discovery by providing the highest quality products at outstanding value, along with superior customer service and technical support.

Professor Ghaleb Al Hadrami, the Deputy Vice Chancellor for Research and Graduate Studies, said that the university supports scientific excellence and innovation and said that, "there were four international competitors negotiating for the license, however our office chose BioLegend due to their leading position in developing and manufacturing world-class, cutting-edge immunological reagents for biomedical research." He also noted the efforts of Mohamed Al Hemairy, Head of Patents and Technology Transfer at the university, and said that, "this deal took over a year of discussion before reaching a mutual consensus. Licensing biochemistry patents in the neurological sciences is challenging due to the complexity of the technology, as well as the time it requires to negotiate the details of the agreement especially when it involves human experimentation."

The driving force behind this technology is Professor Omar El-Agnaf and his team of experienced postdoctoral and postgraduate researchers in the College of Medicine and Health Sciences at UAEU. They developed assays for the detection of proteins involved in Parkinson's Disease. Between seven to ten million people worldwide live with Parkinson's Disease and the lack of early detection is recognised as an impediment to effective clinical intervention as well as retarding the development of new therapeutics.

United Arab Emirates University

Related Technology Articles:

The science and technology of FAST
The Five hundred-meter Aperture Spherical radio Telescope (FAST), located in a radio quiet zone, with the targets (e.g., radio pulsars and neutron stars, galactic and extragalactic 21-cm HI emission).
AI technology could help protect water supplies
Progress on new artificial intelligence (AI) technology could make monitoring at water treatment plants cheaper and easier and help safeguard public health.
Transformative technology
UC Davis neuroscientists have developed fluorescence sensors that are opening a new era for the optical recording of dopamine activity in the living brain.
Do the elderly want technology to help them take their medication?
Over 65s say they would find technology to help them take their medications helpful, but need the technology to be familiar, accessible and easy to use, according to research by Queen Mary University of London and University of Cambridge.
Technology detecting RNase activity
A KAIST research team of Professor Hyun Gyu Park at Department of Chemical and Biomolecular Engineering developed a new technology to detect the activity of RNase H, a RNA degrading enzyme.
More Technology News and Technology Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...